Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions

Research output: Contribution to journalArticlepeer-review


Survivin is a structurally unique member of the inhibitors of apoptosis protein (IAP) family that is involved in both control of cell division and inhibition of apoptosis. Its anti-apoptotic function seems to be related to its ability to directly or indirectly inhibit caspases, although the precise role of survivin in the modulation of the caspase cascade has not been fully elucidated. Survivin has been described to be selectively expressed in the most common human neoplasms and to be associated with clinical tumour progression. Moreover, the protein appears to be involved in tumour cell resistance to some anticancer agents and ionizing radiation. On the basis of these findings survivin has been proposed as a promising target for new anticancer interventions. In in vitro and in vivo studies targeting survivin with antisense oligonucleotides, dominant negative mutants or ribozymes have shown to induce apoptosis, reduce tumour-growth potential and sensitise tumour cells to chemotherapeutic drugs such as Taxol®, cisplatin and etoposide, γ-irradiation, and immunotherapy.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalDrug Resistance Updates
Issue number2
Publication statusPublished - Apr 2002


  • Anticancer drugs
  • Antisense oligonucleotides
  • Apoptosis
  • Dominant negative mutants
  • Ionizing radiation
  • Ribozymes
  • Survivin

ASJC Scopus subject areas

  • Cancer Research
  • Infectious Diseases
  • Oncology
  • Pharmaceutical Science


Dive into the research topics of 'Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions'. Together they form a unique fingerprint.

Cite this